Group B vitamins protect murine cerebellar granule cells from glutamate/NMDA toxicity

NeuroReport

Volumn 15, Issue 14, 2004, Pages 2241-2244

  Lin, Yanpeng ^a,b   Desbois, Angele ^b   Jiang, Susan ^b   Hou, Sheng T ^b  

^a The 252 Hospital of Chinese PLA   (China)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

B group vitamins; Cerebellar granule neurons; Cynocobalamin; Excitotoxicity; Folic acid; Glutamate; NMDA; Riboflavin

Indexed keywords

CARNITINE; CYANOCOBALAMIN; FOLIC ACID; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID; NICOTINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN B GROUP;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN FUNCTION; CELL DEATH; CELL PROTECTION; CEREBELLUM; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; GRANULE CELL; MOUSE; NERVE CELL; NERVE CELL EXCITABILITY; NERVE EXCITABILITY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; VITAMIN INTAKE;

ANIMALS; CELL DEATH; CELLS, CULTURED; CEREBELLUM; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTAMIC ACID; MICE; MICE, INBRED C57BL; N-METHYLASPARTATE; NEURONS; NEUROPROTECTIVE AGENTS; RIBOFLAVIN; VITAMIN B 12; VITAMIN B COMPLEX;

EID: 6344241290     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200410050-00020     Document Type: Article

References (25)

1. Hanley DF. The challenge of stroke prevention. JAMA 2004; 291:621-622.
2. Aarts MM and Tymianski M. Molecular mechanisms underlying specificity of excitotoxic signaling in neurons. Curr. Mol. Med 2004; 4:137-147.
3. Hou ST and MacManus JP. Molecular mechanisms of cerebral ischemia-induced neuronal death. Int Rev Cytol 2002; 221:93-148.
4. Sattler R, Xiong Z, Lu WY, MacDonald JF and Tymianski M. Distinct roles of synaptic and extrasynaptic NMDA receptors in excitotoxicity. J Neurosci 2000; 20:22-33.
5. Prass K and Dirnagl U. Glutamate antagonists in therapy of stroke. Restor Neurol Neurosci 1998; 13:3-10.
6. Hoyte L, Barber PA, Buchan AM and Hill MD. The rise and fall of NMDA antagonists for ischemic stroke. Curr Mol Med 2004; 4:131-136.
7. Toole JJ, Malinow MM and Chambless LL. Lowering homocysteine in patients with ischemic stroke to recurrent stroke, myocardial infarction, and death: the vitamin intervention for stroke prevention (VISP) randomized controlled trial. J Vasc Surg 2004; 39:1356.
8. Toole JF. Vitamin intervention for stroke prevention. J Neurol Sci 2002; 203-204:121-124.
9. Li J, Lin JC, Wang H, Peterson JW, Furie BC, Furie B et al. Novel role of vitamin k in preventing oxidative injury to developing oligodendrocytes and neurons. J Neurosci 2003; 23:5816-5826.
10. Shea TB and Rogers E. Folate quenches oxidative damage in brains of apolipoprotein E-deficient mice: augmentation by vitamin E. Brain Res Mol Brain Res 2002; 108:1-6.
11. Kaneda K, Kikuchi M, Kashii S, Honda Y, Maeda T, Kanekos S et al. Effects of B vitamins on glutamate-induced neurotoxicity in retinal cultures. Eur J Pharmacol 1997; 322:259-264.
12. Wang XD, Kashii S, Zhao L, Tonchev AB, Katsuki H, Akaike A et al. Vitamin B6 protects primate retinal neurons from ischemic injury. Brain Res 2002; 940:36-43.
13. He K, Merchant A, Rimm EB, Rosner BA, Stampfer MJ, Willett WC et al. Folate, vitamin B6, and B12 intakes in relation to risk of stroke among men. Stroke 2004; 35:169-174.
14. Chang GY. Acute Wernicke's syndrome mimicking brainstem stroke. Eur Neurol 2000; 43:246-247.
15. Napolitano A, Salvetti S, Vista M, Lombardi V, Siciliano G and Giraldi C. Long-term treatment with idebenone and riboflavin in a patient with MELAS. Neurol Sci 2000; 21:S981-S982.
16. Thompson JE, Smith M, Castillo M, Barrow M and Mukherji SK. MR in children with L-carnitine deficiency. Am J Neuroradiol 1996; 17:1585-1588.
17. Miller JW, Green R, Mungas DM, Reed BR and Jagust WJ. Homocysteine, vitamin B6, and vascular disease in AD patients. Neurology 2002; 58:1471-1475.
18. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291:565-575.
19. Diaz-Arrastia R. Homocysteine and neurologic disease. Arch Neurol 2000; 57:1422-1427.
20. Hou ST, Cowan E, Walker T, Ohan N, Dove M, Rasqinha I et al. The transcription factor E2F1 promotes dopamine-evoked neuronal apoptosis by a mechanism independent of transcriptional activation. J Neurochem 2001; 78:287-297.
21. Sattler R, Charlton MP, Hafner M and Tymianski M. Determination of the time course and extent of neurotoxicity at defined temperatures in cultured neurons using a modified multiwell plate fluorescence scanner. J Cerebr Blood Flow Metab 1997; 17:455-463.
22. Gupta S, Kaul CL and Sharma SS. Neuroprotective effect of combination of poly (ADP-ribose) polymerase inhibitor and antioxidant in middle cerebral artery occlusion induced focal ischemia in rats. Neurol Res 2004; 26:103-107.
23. Sakakibara Y, Mitha AP, Ayoub LA, Ogilvy CS and Maynard KI. Delayed treatment with nicotinamide (vitamin B3) reduces the infarct volume following focal cerebral ischemia in spontaneously hypertensive rats, diabetic and non-diabetic Fischer 344 rats. Brain Res 2002; 931:68-73.
24. Katunuma N, Murata E, Kakegawa H, Matsui A, Tsuzuki H, Tsuge H et al. Structure based development of novel specific inhibitors for cathepsin L and cathepsin S in vitro and in vivo. FEBS Lett 1999; 458:6-10.
25. Shen CC, Huang HM, Ou HC, Chen HL, Chen WC and Jeng KC. Protective effect of nicotinamide on neuronal cells under oxygen and glucose deprivation and hypoxia/reoxygenation. J Biomed Sci 2004; 11:472-481.